Sitka Gold Reports High-Grade Drill Results from Contact Zone at RC Gold Project
Sitka Gold Corp. announced new drill results from its RC Gold Project in the Yukon, including an intersection of 74.8 metres of 1.31 g/t gold.
Stocks · News reference
Crude Oil Jumps Over 3%; Core & Main Posts Upbeat Q2 Earnings
U.S. stocks fell Wednesday as energy rose and discretionary slumped; Signet and Opus surged, while ServiceTitan plunged. Oil jumped 3.6%.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — SIGNET JEWELERS LTD (SIG)
Filed: 2026-11-05 AccNo: 0000832988-26-000240 Size: 403 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 9.01: Financial Statements and Exhibits
ServiceTitan Announces Date for Fiscal Third Quarter 2027 Financial Results
ServiceTitan, Inc. has scheduled the release of its financial results for the fiscal third quarter ended October 31, 2026, for December 3, 2026.
Casey's General Stores Has Fallen 10% Since Reporting Earnings. Is It a Buy in November?
Casey's General Stores stock dropped 10% after reporting fiscal Q1 2027 earnings despite strong top and bottom-line results. While earnings rose 27% year-over-year and same-store sales grew 3.2%, the growth rate was the lowest in five quarters. The stock remains expensive with a P/S ratio of 1.3x (vs. 5-year average of 0.8x) and P/E of 32x (vs. 5-year average of 26x), suggesting investors have priced in high expectations that the company is failing to exceed.
Sitka Gold Corp. Reports Drilling Results from Bear Paw Zone
Sitka Gold Corp. announced new drilling results from its Bear Paw Zone, confirming the continuity of high-grade mineralization.
Opus Genetics Completes Dosing in Cohort 2 of Phase 1/2 Clinical Trial of OPGx-BEST1
Opus Genetics has finished dosing the second cohort in its BIRD-1 Phase 1/2 clinical trial evaluating OPGx-BEST1 for the treatment of inherited retinal diseases.